Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Table 3 Unadjusted risk of hospitalization due to heart failure with DPP-4 inhibitors versus GLP-1 agonists in propensity score matched analyses

Cohort	Medications	No. of patients	Person-years	No. of HF events	Crude incidence per 1000 person-years
Overall (primary analysis)	DPP-4 inhibitors	160,803	76,749	5714	74
Overall (primary analysis)	GLP-1 agonists	160,803	70,469	6098	87
Baseline HF
Absent	DPP-4 inhibitors	158,543	75,545	5533	73
Absent	GLP-1 agonists	158,543	69,682	5870	84
Present	DPP-4 inhibitors	1937	686	194	283
Present	GLP-1 agonists	1937	739	212	287
Baseline CVD
Absent	DPP-4 inhibitors	132,047	62,552	3204	51
Absent	GLP-1 agonists	132,047	58,366	3487	60
Present	DPP-4 inhibitors	28,085	13,544	2579	190
Present	GLP-1 agonists	28,085	11,835	2579	218
Individual drugs
Saxagliptin	Saxagliptin	49,214	19,302	1335	69
Saxagliptin	GLP-1 agonists	49,214	20,741	2058	99
Sitagliptin	Sitagliptin	160,609	81,573	6108	75
Sitagliptin	GLP-1 agonists	160,609	70,441	6239	89

CI confidence interval, CVD cardiovascular diseases, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, HF heart failure, HR hazard ratio

ISSN: 1475-2840